CTOs on the Move

Seattle Institute for Biomedical and Clinical Re

www.sibcr.org

 
Seattle Institute for Biomedical and Clinical Research is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sibcr.org
  • 1660 S Columbian Way
    Seattle, WA USA 98108
  • Phone: 206.764.2730

Executives

Name Title Contact Details

Similar Companies

POINTONE Systems

POINTONE Systems is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioAmber

BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.

iChip

LifeNexus is the creator of iChip, a product that empowers consumers with their health information anywhere they need it. By working with health plans, employers and providers, we`re helping to create better healthcare experiences when it matters most.

Essentia Biosystems

Essentia Biosystems is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rare Cancer Research Foundation

The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.